Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07414992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

StatusWithdrawn
PhasePhase 2
Started2026-09
View on ClinicalTrials.gov ↗
Why the trial stopped
The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target patient population.

Amendment history

2026-09-01
Study Status, Study Design, Contacts/Locations v4
Withdrawn before enrolling
Trial withdrawn: The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target p...
Enrollment targetestimated 44→confirmed 0
Study sitescontacts updated at 7 of 7 sites
2026-08-17
Study Status v3
Start date2026-07→2026-09
2026-06-23
Study Status v2
Start date2026-05→2026-07
2026-04-30
Study Status v1
Start date2026-03→2026-05
2026-02-11
Original filing
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).
Trial Details
NCT Number NCT07414992
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Regeneron Pharmaceuticals
Conditions Bladder Urothelial Carcinoma
Start Date 2026-09
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-03